Ranked #3,106 of 8,699 institutional investors
Atlas Venture Life Science Advisors, LLC
Cambridge, MA
$641M
US stock portfolio at live prices · today −$15.3M (−2.33%)
Live prices, last trade 12:21 PM ET
- Value at quarter end (Q3 2026)
- $631M
- Change from Q2 2026
- −$250.1M (−28.38%)
- Positions
- 9 · 2 new, 0 sold out
- Filed
- Nov 10, 2026
Holdings
Q3 2026 13F, live pricesKYMR 51.4%IRON 16.1%KLRA 9.24%DYN 8.47%OBX 8.39%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KYMR Kymera Therapeutics, Inc. | 2,847,541 | $329M | 51.4% | Unchanged |
| IRON Disc Medicine, Inc. | 1,384,025 | $103M | 16.1% | Reduced −9% |
| KLRA Kailera Therapeutics, Inc. | 5,171,282 | $59.3M | 9.24% | Unchanged |
| DYN Dyne Therapeutics, Inc. | 3,440,720 | $54.3M | 8.47% | Reduced −49% |
| OBX Obsidian Therapeutics, Inc. | 4,503,149 | $53.8M | 8.39% | New |
| QTTB Q32 Bio Inc. | 2,717,106 | $22.9M | 3.57% | Unchanged |
| KRRO Korro Bio, Inc. | 773,260 | $9.6M | 1.49% | Reduced −20% |
| SION Sionna Therapeutics, Inc. | 2,995,602 | $8.6M | 1.34% | Unchanged |
| ODTX Odyssey Therapeutics, Inc. | 2,692 | $46K | <0.1% | New |